Evommune Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	10	13	7	5
Revenue Growth (YoY)	233.33%	85.71%	40.00%	-
Gross Profit	10	13	7	5
Selling, General & Admin	22.99	20.03	12.77	10.85
Research & Development	77	74.04	64.24	32
Total Operating Expenses	99.99	94.07	77.01	42.85
Operating Income	-89.99	-81.07	-70.01	-37.85
Interest Income	4.99	3.32	3.24	3.86
Other Non-Operating Income (Expense)	9.01	8.88	-0.04	-0.06
Total Non-Operating Income (Expense)	14.01	12.2	3.21	3.8
Pretax Income	-75.99	-68.87	-66.81	-34.05
Net Income	-54.81	-68.87	-68.31	-34.05
Net Income Attributable to Preferred Dividends	-	-	1.5	-
Net Income to Common	-54.81	-68.87	-68.31	-34.05
Shares Outstanding (Basic)	14	6	2	1
Shares Outstanding (Diluted)	14	6	2	1
Shares Change (YoY)	827.45%	306.86%	20.35%	-
EPS (Basic)	-18.95	-11.22	-45.29	-27.17
EPS (Diluted)	-18.95	-11.22	-45.29	-27.17
Shares Outstanding	36.02	31.52	1.55	1.55
Free Cash Flow	-80.36	-76.68	-58.28	-30.09
Free Cash Flow Per Share	-5.69	-12.49	-38.64	-24.01
Gross Margin	100.00%	100.00%	100.00%	100.00%
Operating Margin	-899.92%	-623.62%	-1000.19%	-757.00%
Profit Margin	-759.87%	-529.77%	-954.40%	-681.06%
FCF Margin	-803.63%	-589.82%	-832.61%	-601.76%
EBITDA	-88.63	-79.68	-68.73	-36.85
EBITDA Margin	-886.31%	-612.94%	-981.80%	-737.00%
EBIT	-89.99	-81.07	-70.01	-37.85
EBIT Margin	-899.92%	-623.62%	-1000.19%	-757.00%

SEC Filings: 10-K · 10-Q